Please wait...

You selected inventions in category Life Sciences

  • Patents related with GIPsFILIP1L filamin A-interacting protein 1-like proteinsPatents related with GIPsFILIP1L filamin...
      Preview
      Description

      In Fibrostatin SL we have some issued patents related with GIPs/FILIP1L (filamin A-interacting protein 1-like) proteins that we would like to sell or license. The patents are:

      US Patent 7147855, US Patent 7601349, Australia Patent 2002365637, Japan Patent 4201712.

      The invention provides isolated GPBP-interacting 90 and 130 kDa polypeptides, and portions thereof (GIP90/130 polypeptides), antibodies to the GIP90/130 polypeptides, and pharmaceutical compositions thereof. The present invention also provides isolated GIP90/130 nucleic acid sequences, expression vectors comprising the nucleic acid sequences, and host cells transfected with the expression vectors.

      FILIP1L proteins have been recognized as putative targets in cancer (Kwon M, Libutti SK.. 2014. Expert Opin Ther Targets. 18:1435-47.). GIPs are 90-kDa and 130-kDa FILIP1L isoforms that bind to Goodpasture antigen binding protein (GPBP) also known as Ceramide transfer protein or CERT. FILIP1L-130 kDa and GPBP are involved in myofibril formation (Revert-Ros et al. 2011. J Biol Chem. 286:35030-43.)

      Full details Contact close
    • DIAGNOSTIC TEST OF STREPTOCOCCUS AGALACTIAE INFECTIONS  IN PREGNANT WOMENDIAGNOSTIC TEST OF STREPTOCOCCUS AGALACTIAE...
        Preview
        Description

        The offer is a new diagnostic test which may confirm the Streptococcus agalactiae infections in pregnant women. The proposed test uses a specific reaction of immunoreactive proteins derived from clinical isolates of S. agalactiae with the antibodies present in the serum of patients, and provides an alternative to commonly used solutions in this field.

        Full details Contact close
      • Jiang Xi JiaHuaMei Shell development Co LTDJiang Xi JiaHuaMei Shell development Co LTD
          Preview
          Description

          Jiang Xi JiaHuaMei Shell development Co., LTD is a professional manufacturer of natural, environmental protection, pollution-free green products, mainly hand craftsmanship and modern technology, manufacturing tools jewel-level processing methods combined with the variety of high-quality natural mother of pearl natural color and texture characteristics of the body, so that shell pearl, color demonstrated most vividly, the company has developed into a research and development, production, sales as one of the private manufacturers.
          The main products are various shell mosaic, shell decorative boards, shell tiles, shell puzzles, shell crafts,Tiger's Eye Stone ,Agate Slab,Marble Mosaic,Mixed Mosaic etc.The products are widely used in clubs, bars, hotels, villas, lighting, furniture and home decoration.
          We commits to provide finest products and best customer service the worldwide market, so that more people can enjoy the great visual of our products .Our customers are from all around the world,we only offer the best for our customer !
          Trust us , choose us,you will get the best !

          Full details Contact close
        • A new drug for the prevention and treatment of human influenza A virus IAV human metapneumovirus hMPV and human rhinoviruses HRVA new drug for the prevention and treatment of...
            Preview
            Description

            Potential drug: a modified polyallylamine derivative

            Application: prevention and treatment of human influenza A virus (IAV), human metapneumovirus (hMPV) and human rhinoviruses (HRV)

            Influenza is an acute infectious disease caused by viruses belonging to the Orthomyxoviridae family, and classified into three types: A, B and C. This classification is based on antigenic differences between the major virion proteins, e.g. M protein and nucleoprotein NP. These types differ in terms of epidemiological properties.

            Influenza A virus (IAV) causes acute and chronic respiratory infections. It is a major respiratory pathogen of humans and animals. A period of frequent influenza infections occurs each winter (seasonal flu, the highest incidence occurring
            in January/February). Only type A influenza virus causes epidemics and pandemics because of antigenic shift that is multiple changes in the various genome segments resulting from reassortment of different strains of the virus.

            According to the World Health Organization (WHO) infections with influenza
            and influenza-like viruses occur globally with an annual attack rate estimated at 5%-10% in adults and 20%-30% in children. Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths. The most severe infections develop in children under two years of age, in the elderly aged 65 or older and in those with compromised immunity. WHO recommends vaccination against the influenza virus as the most effective way to prevent infections. On the other hand, because of a large variability of the virus, the difficulty in obtaining sufficient number of vaccines before the epidemic wave, and not always satisfactory efficacy of the vaccine and anti – influenza drugs, the disease still represents an important medical and epidemiological problem. Therefore, new effective drugs for the anti-influenza treatment are needed.

            The new invention of the Jagiellonian University, which is the subject
            of the proposed offer, discloses a new drug for the treatment of human A virus (IAV) infection.

            Human metapneumovirus (hMPV) was identified in 2001, however, it was proved that infections with this pathogen have occurred in the human population for
            at least 50 years now. It is the only known Pneumovirus which infects humans and causes both upper and lower respiratory tract infections. Respiratory infections caused by hMPV have been reported in patients of every age and gender,
            but children under 5 years are most likely to be susceptible to infections caused
            by hMPV. The clinical manifestations of hMPV disease are flu-like symptoms such
            as runny nose, cough, sore throat and high fever. The virus is widespread, and is found on all continents. Late winter and early spring is the epidemic peak of hMPV infections. More serious symptoms, including severe lower respiratory tract infections, are found mainly in young children and infants under 5 years
            of age, elderly individuals above 60 years of age, and immunocompromised patients, whereas immunocompetent adults present mostly flu-like illnesses or cold symptoms.
            So far, no other drug has been approved for inhibition and prevention
            of infections caused by hMPV. By 2012, the only drugs with broad spectrum
            of activity (such as ribavirin and immunoglobulins) have been used to treat very acute, severe hMPV infections of patients after lung transplantation. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of human metapneumovirus (hMPV) infection.

            The human rhinovirus (HRV) belongs to the smallest known viruses (their diameter does not exceed 30 nm). During the year, particularly in winter and spring, it causes infections of the upper respiratory tract with humans, appearing as the common cold. Rhinoviruses also cause otitis media, sinusitis and inflammations of the lower respiratory tract, including bronchi

            Full details Contact close
          • Novel antiviral agent based on modified chitosanNovel antiviral agent based on modified chitosan
              Preview
              Description

               Medical background: Coronaviruses (CoV) cause many diseases in humans
              and animals; in particular, human pathogens include HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1 and SARS-CoV. The latter causes a condition called Severe Acute Respiratory Syndrome (SARS) – an atypical pneumonia that first appeared in China in 2002. Until now, no effective cure for SARS has been introduced into the clinic, and the treatment of that disease is merely symptomatic. Viruses of this group are also responsible for serious diseases in animals. This fact is important not only in terms of the risk of transmission into human population (the SARS case), but also – in the case of farming animals – for economic reasons.
               Potential antiviral agent: modified natural polysaccharides (chitosan polymer).
               Application: treatment and prevention of viral infections caused by coronaviruses in humans, including respiratory diseases manifested by impaired respiratory function.
               Key features:
              • Development stage: preclinical phase.
              • IP status: several international patent application: EPO, USA, Canada, Japan, China, India (November, 2014).
              • Confirmed ability to efficient bind of coronaviruses and inhibit their replication in vitro and/or ex vivo.
              • Modified chitosan has antibacterial and antifungal activity, which is
              an additional advantage of the offered polymer.
              • The possibility to apply as a solution or spray administrated either topically to the upper respiratory tract (throat, nose, bronchial tree), orally in the case of gastrointestinal infections or intravenously for systemic therapy.

              Licensor information
              The Jagiellonian University, located in Kraków, Poland, is one of the oldest universities in Europe. The offered inventions have been developed by researchers of the Faculty of Chemistry and Faculty of Biochemistry, Biophysics
              and Biotechnology of the Jagiellonian University.

              Full details Contact close
            • A NEW DRUG FOR THE PREVENTION AND TREATMENT OF HERPES SIMPLEX VIRUS HSV-1A NEW DRUG FOR THE PREVENTION AND TREATMENT OF...
                Preview
                Description

                Herpes simplex virus 1 (HSV-1), is one of the most commonly encountered pathogens in humans. The most recent statistics indicate that approximately 50-90% of the world population is HSV-1 seropositive. The most common primary infections are cold sores occurring mainly on the face (especially the skin, tongue and lips). However, infection with HSV-1 may also lead to severe diseases such as inflammation of the eye or encephalitis. These diseases are characterized by severe course and may cause permanent adverse health effects (e.g. blindness), and even death.

                Currently, there are several antiviral drugs, which are active against pathogens belonging to the Herpesviridae family. These drugs reduce the frequency and severity of relapses and also alleviate bothersome symptoms during the primary infection. Although they are usually only effective for the initial infection, they do not eliminate a virus in a latent state and thus do not protect a person before re-emergence of symptoms. There has also been increasing emergence of drug resistant viral strains. Thus, there is a need to find a new approach to developing effective treatment of HSV-1 infection. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of herpes simplex virus (HSV-1) infection.

                The main advantages of the offered drug are:
                 confirmed ability to efficient bind of herpes simplex virus (HSV-1)
                and inhibit its replication in vitro,
                 low-toxicity of the drug in vitro,
                 the possibility to apply as an ointment or solution administrated either topically to the skin or eye, orally, intraperitoneally or intravenously.

                The offered invention is subject of a patent application. Further research
                and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the Centre for Technology Transfer CITTRU is looking for partners interested in the development of the invention and its commercial application.

                More information:
                PhD Klaudia Polakowska – Technology Transfer Officer
                phone. +48 12 663 3832, +48 519 329 129, klaudia.polakowska@uj.edu.pl

                Full details Contact close
              • ToysCollectorToysCollector
                  Preview
                  Description

                  Toys-collector main serve for toy enthusiasts and distributor,we professional to supply Transformer,Original Car Model, UAV,Autobots and so on by wholesale and retail. And freeshipping online store.If you are interesed in this kind of toys,please feel free to contact us,or log in our website to have a look first:http://www.toys-collector.com/

                  Full details Contact close
                • Amylase assay hemolysis interference-freeAmylase assay hemolysis interference-free
                    Preview
                    Description

                    Although the assessment of α-amylase is an essential part of the diagnostic workout of several pancreatic and extra-pancreatic disorders, its enzymatic activity is significantly reduced in the presence of cell-free hemoglobin such as in samples with spurious hemolysis, due to chemical and spectrophotometric interference. We developed a new reagent that provides reliable results on hemolyzed biological specimens.
                    The clinical applications of the experimental reagent include α-amylase assessment in hemolyzed samples, in urine and other biological fluids contaminated with lysed erythrocytes, or in patients under frequent transfusions and hemoglobin-based blood substitutes therapy. The formulation of this reagent could be adapted for other clinical chemistry or immunochemistry assays.
                    See publication at: http://www.ncbi.nlm.nih.gov/pubmed/23420287

                    Full details Contact close